Exelixis (EXEL) Cash from Operations Growth (3y) (2013 - 2026)
Exelixis (EXEL) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 34.32% |
| 10 | Exelixis | 14.52 Bn | 13.75 Bn | 590.86 Mn | 43.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 43.96% |
| Jan 2, 2026 | 65.41% |
| Oct 3, 2025 | 38.17% |
| Jul 4, 2025 | 16.32% |
| Apr 4, 2025 | 12.70% |
| Jan 3, 2025 | 35.56% |
| Sep 27, 2024 | 48.23% |
| Jun 28, 2024 | -12.99% |
| Mar 29, 2024 | 20.29% |
| Dec 29, 2023 | 27.36% |
| Mar 31, 2023 | 14.61% |
| Sep 30, 2022 | 13.33% |
| Jul 1, 2022 | -38.17% |
| Apr 1, 2022 | -2.95% |
| Dec 31, 2021 | -2.66% |
| Oct 1, 2021 | -20.35% |
| Jul 2, 2021 | 34.58% |
| Apr 2, 2021 | -18.03% |
| Jan 1, 2021 | -70.97% |
| Apr 3, 2020 | -6.62% |